SPL7013 Gel (VivaGel®) Retains Potent HIV-1 and HSV-2 Inhibitory Activity following Vaginal Administration in Humans

Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women

(2011) Salim S Abdool Karim et al.   AIDS

PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial

(2010) Sheena McCormack et al.   LANCET

Postcoital Bioavailability and Antiviral Activity of 0.5% PRO 2000 Gel: Implications for Future Microbicide Clinical Trials

(2010) Marla J. Keller et al.   PLoS One

Anti-HIV Activity in Cervical-Vaginal Secretions from HIV-Positive and -Negative Women Correlate with Innate Antimicrobial Levels and IgG Antibodies

(2010) Mimi Ghosh et al.   PLoS One

Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral Activity

(2010) David Tyssen et al.   PLoS One

Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women

(2010) Q. Abdool Karim et al.   SCIENCE

Safety, Tolerability, and Pharmacokinetics of SPL7013 Gel (VivaGel®): A Dose Ranging, Phase I Study

(2010) John OʼLoughlin et al.   SEXUALLY TRANSMITTED DISEASES

Enhancement of Human Immunodeficiency Virus Type 1 Replication Is Not Intrinsic to All Polyanion-Based Microbicides

(2009) S. Sonza et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Randomized Controlled Trial of the Safety of Candidate Microbicide SPL7013 Gel When Applied to the Penis

(2009) Marcus Y Chen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Development of a Comprehensive Human Immunodeficiency Virus Type 1 Screening Algorithm for Discovery and Preclinical Testing of Topical Microbicides

(2008) C. Lackman-Smith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY